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Background: To determine the importance of spirometric testing for early detection of chronic 
obstructive pulmonary disease (COPD).
Methods: Spirometric testing has been performed annually on World COPD Day in Sezana from 
2003. Sezana is in a semiurban region of Slovenia, with 12,000 inhabitants. The investigation 
was performed between January 2003 and December 2008. In total, 770 persons were enrolled 
(414 females and 356 males). The participants were recruited by mass media appeals.   Smokers 
aged $40 years with a smoking history of $10 pack-years were invited to visit the local chest 
clinic. The participants completed a questionnaire and had spirometry performed. Subjects 
with a postbronchodilator forced expiratory volume in one second/forced vital capacity ,0.70 
were defined as having COPD, according to the Global Initiative for Chronic Obstructive Lung 
Disease guidelines.
Results: We identified that 16.2% of subjects had impaired lung function. Of these, 10.2% had 
an obstructive pattern of ventilatory impairment and 6% had a restrictive pattern. We identified 
79 individuals with COPD. Subjects with COPD were .70 years in 40.5% in cases. The 
majority of individuals with COPD were men (74.6%), and 90% were smokers. COPD was 
mild in 52% of subjects, moderate in 34%, and severe in 14%. The majority of subjects had a 
milder stage of the disease, and 92% of those with COPD (72/79) had not been recognized to 
have COPD previously.
Conclusion: These results suggest that spirometry testing could detect patients with COPD in 
the earlier stages of the disease.
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Introduction
COPD is one of the leading causes of morbidity and mortality in industrialized countries 
worldwide, and is emerging as being increasingly important in developing countries.1–4 
Assuming that current trends in mortality continue, COPD will move from being the 
sixth leading cause of death worldwide in 1990 to the third in 2020.5 Epidemiological 
studies in Europe have demonstrated that COPD affects about 9% of the adult popula-
tion, mostly smokers.6,7 The disease is poorly recognizable by both patients and health 
care providers, especially in the earlier stages.8,9 Population-based surveys that have 
used spirometry have documented the underdiagnosis of COPD.9–12 For example, a 
Korean survey found that 17.2% of Korean adults over the age of 45 years have mild 
COPD and only a minority had been diagnosed.11 In the PLATINO study, 88.7% of 
COPD cases had not been previously diagnosed.12 Underdiagnosis was related to International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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severity of COPD, because milder disease is missed more 
often than severe disease.11,12
Materials and methods
Study design and population
This study was conducted at Sezana Hospital in Sezana, 
a town in the southwestern part of Slovenia. The aim was 
to evaluate the usefulness of spirometric testing for early 
detection of airflow obstruction. The testing was first 
started on World COPD Day 2003, and then we   continued 
to   perform free spirometric testing annually on this day. 
Our target population was the inhabitants of Sezana,   current 
and former smokers aged $40 years, with a   smoking 
  history of $10 pack-years. Inclusion criteria were aged 
above 40 years and a   history of smoking (.10 pack-years), 
  exclusion criteria were the presence of any other   pulmonary 
disease and comorbid conditions that preclude use of 
spirometry. Although the target population was defined as 
smokers aged $40 years, it was decided that never-smokers 
who were concerned about their lung health would be 
included in the project.
The participants were invited by mass media appeals 
(advertisements on TV , radio, newspapers) and billboards 
displayed in public places. Primary care physicians were 
asked to encourage eligible patients to participate in the 
project. The study was approved by the local hospital ethics 
committee, and all participants gave their written informed 
consent. Spirometric testing was conducted in two parts. The 
first part was conducted from 2004 to 2006, and the second 
part was conducted from 2006 to 2008.
Questionnaire data
All subjects completed a questionnaire seeking demographic 
and anthropometric data, history of smoking, cough, 
expectoration, dyspnea, and allergies.
Tests
Spirometry was performed by an experienced certified 
technician at the lung function laboratory of the Hospital 
Sezana. Forced expiratory volume in one second (FEV1) 
and forced vital capacity (FVC) were recorded according to 
American Thoracic Society recommendations13 using a flow 
screen Jaegar spirometer (Jaeger, Wuertzburg,   Germany), 
with participants in a seated position. This spirometer 
  fulfils the American Thoracic Society criteria.13 After initial 
  spirometry, a bronchodilatory test was performed with inha-
lation of salbutamol (GlaxoSmithKline, Montrose, United 
Kingdom) 100 µg four puffs to all subjects, administered 
via a metered-dose inhaler with a spacer. After an additional 
15 minutes, postbronchodilator spirometry was performed. 
Two investigators independently assessed the quality of the 
flow-volume curves according to the criteria of the American 
Thoracic Society.13 To be deemed usable for the analysis, 
spirometry had to meet American Thoracic Society accept-
ability and reproducibility criteria.
Definitions
In accordance with the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) guidelines, irreversible   airflow 
obstruction was defined as a postbronchodilator FEV1/FVC 
ratio of ,0.70, which corresponds to GOLD Stage I.14,15 
Airflow obstruction was classified according to the GOLD 
criteria. Severity of COPD is distinguished in four stages:
•	 Mild (GOLD Stage I) FEV1/FVC ratio ,0.70 and 
FEV1 . 80% predicted
•	 Moderate (GOLD Stage II) FEV1/FVC ratio ,0.70 and 
FEV1 50%–80% predicted
•	 Severe (GOLD Stage III): FEV1/FVC ratio ,0.70 and 
FEV1 30%–50% predicted
•	 Very severe (GOLD Stage IV): FEV1/FVC ratio ,0.70 
and FEV1 , 30% predicted or FEV1 , 50% with signs 
of chronic respiratory failure.
Predicted values for FEV1 and FVC were computed using 
the regression equations of the European Coal and Steel 
  Community approved by the European   Respiratory Society.16 
The values for FEV1/FVC and FEV1 were   postbronchodilator, 
and were expressed as a percentage of predicted. The GOLD 
  definition of reversibility was used, ie, FEV1 increase 
of 200 mL and 12% improvement above baseline FEV1 
following the administration of bronchodilator. Doctor-
diagnosed COPD was defined as self-reported physician’s 
diagnosis of chronic bronchitis, emphysema, or COPD. The 
number of pack-years of cigarette smoking was defined as 
the average number of cigarettes smoked per day divided 
by 20 (ie, packs per day) times the duration of smoking in 
years. The participants identified to have COPD were sent 
for further investigation and treatment at the Department of 
Pneumonology, Sezana Hospital.
Data presentation and statistics
Continuous variables are expressed as the mean (±standard 
deviation) and prevalence rates as crude and standardized 
gender-adjusted values. The Student’s t-test was used to 
compare continuous variables, and Chi-square values were International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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used for testing between groups of frequencies. P , 0.05 
was considered statistically significant.
Results
Of the 1254 individuals contacted, 110 were not eligible on 
the basis of age. Of the remaining 1144 eligible participants, 
770 (67%) completed the questionnaire data, and had 
spirometry findings that met American Thoracic Society 
quality control criteria. These individuals constituted the 
final sample for the analysis. In total, 329 persons (29%) 
did not complete the questionnaire data, and 45 individuals 
(4%) completed the questionnaire data but had unusable 
spirometry (see Figure 1).
The final sample consisted of 356 males (46%) and 
414 females (54%). The average age was 59.6 ± 14.8 years, 
for females 60 ± 13.6 years, and for males 58.2 ± 16.0 years. 
One quarter of the participants were aged 40–50 years, and 
almost half of them were aged 50–70 years. The remaining 
individuals were older than 70 years (see Table 1).
Two-hundred and seventy-eight subjects (36.1%) were 
current smokers, 178 (23.1%) were former smokers, and 
314 (40.8%) were never-smokers. Significantly (P , 0.001) 
more males (201, 56.5%) than females (77, 18.6%) were 
current smokers. The opposite was found among former 
smokers, in that 57 males and 121 females were former 
smokers (16.0% versus 29.2%, P , 0.001). Males had 
an average smoking history of 26.1 ± 2 pack-years and 
females 16.5 ± 4 pack-years. Smoking intensity above 
15 pack-years was reported by 148 (52.2%) current smokers 
(see Table 2).
The results of spirometry were within normal limits for 
645 subjects (83.8%) and a pattern of ventilatory impair-
ment was found in 125 subjects (16.2%). Among these, 
79 subjects (10.2%) had airflow limitation (obstruction) and 
46 subjects (6.0%) had a restrictive pattern of ventilatory 
impairment (see Table 3). Table 4 reports spirometry in the 
study participants.
COPD was diagnosed in 79 subjects (10.2%). Of these, 
41 persons (52%) had the mild form (GOLD I), 27 persons 
(34%) had the moderate form (GOLD II), and 11 (14%) had 
the severe form of the disease. None had the severe stage of 
disease (GOLD IV). The majority of patients had mild stage 
of the disease (GOLD I). Fifty-nine patients with COPD 
(74.6%) were men (see Figure 2).
The prevalence of airways obstruction increased with age, 
from six patients (7.6%) in the fourth decade to 33 patients 
(40.5%) aged 70 years or more. The average age of the 
individuals with COPD was 65 years ± 4.0 (Figure 3).
Among patients with COPD, 54 patients were   current 
smokers (68.4%), 17 patients were former smokers (21.5%), 
and eight patients were never-smokers (10.1%). The majority 
of the patients with COPD (80.3%) reported .15   pack-years 
of smoking. A higher proportion of male patients with 
COPD were current smokers, compared with female patients 
Target population 
n = 1254
Found age-ineligible 
n = 110 
Incomplete data questionnaire 
n = 329 
Nonresponders  
 n = 374
Unusable spirometry 
n = 45
Final study sample 
n = 770
Figure 1 Flow diagram of the study population.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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(71.2% versus 60%, P , 0.001). Gender differences also 
existed in terms of mean pack-years. Men were more inten-
sive smokers than women (36 ± 10 pack-years versus 19 ± 10 
pack-years, P , 0.001, Figure 4).
The prevalence of COPD among females was 4.8% and 
was 16.6% among males. The prevalence of COPD in   current 
smokers was 19.4%, 9.6% in former smokers, and 2.6% in 
never-smokers. Seventy-three of 79 with COPD had not 
been recognized prior to this survey. We identified 92% of 
patients with COPD, but previous diagnosis of COPD by a 
doctor was reported by only six patients (8%).
Discussion
The key findings of this survey are that 9.5% of the 
participants had previously undetected COPD, and over half 
of the individuals identified to have COPD (52%) had a mild 
form of this disease. However, this study does have several 
limitations. One is the smallness of the sample size and that 
the recruitment was based on voluntary participation, so was 
not representative of the population of Slovenia. The other 
limitation is that the use of the fixed ratio (FEV1/FVC , 0.7) 
as the cutoff point for airflow obstruction, as   recommended 
by GOLD, has the potential for misclassification at 
older ages. The present GOLD guidelines endorse the use 
of the fixed ratio, while recognizing that there is potential 
for misclassification.
A meta-analysis of epidemiological investigations, based 
on spirometry testing, has shown a COPD prevalence in 
the developed world of 8.9% (7.4%–10.7%).17 The COPD 
prevalence in our cohort (10.2%) is consistent with the 
reported COPD prevalence in other epidemiological surveys 
worldwide,17–22 although the comparison of prevalence rates 
for COPD is very difficult because the studies have used 
different methodologies.18–24
Several candidate populations for a screening strategy by 
means of spirometry have been advocated in the available 
literature.25–29 In our survey of spirometric testing, we used the 
strategy of Zielinski and Bednarek for the target population, the 
manner of recruiting the participants, the type of spirometer, 
  regression equations for computing FEV1 and FVC, and the cri-
teria for defining COPD.25 The prevalence of COPD in current 
smokers in this study was 19.4%, which is in accordance with 
other international epidemiological studies.10,30
The gender-standardized COPD prevalence in our survey 
was 15.7% for men and 5.5% for woman, which can be 
explained with the difference in smoking intensity. Given 
the increasing smoking rate among women in recent decades, 
one may expect that the prevalence of airflow obstruction in 
female smokers will rise in the near future.31
Although tobacco smoking is the main risk factor for 
COPD, other factors could be involved in its development.26 
However, the prevalence of COPD in our survey among 
never-smokers was low at 2.6%. Some studies that have 
detected the prevalence of COPD included never-smokers, 
in which case the prevalence was 20.4%–30%,11,32 and other 
studies excluded never-smokers.12
Our investigation shows that the prevalence of airway 
obstruction increased with age, with the highest prevalence 
Table 3 Pulmonary function in the study participants
Pulmonary  
function
Male Female Total t-value P value
M SD M SD M SD
Fev1 (L) 3.30  1.2 3.1 1 3.22  1.12 2.281 0.023*
Fev1 (% of  
predicted)
0.99  17.2 0.97 19.8 0.98  18.63 1.651 0.099
FvC (L) 4.40  2.0 4.09  1.9 4.25 2.01 2.163 0.031*
Fev1/FvC  
ratio
75.16  7.4 75.6 10.0 75.4  8.91 -0.725 0.468
Note: *Statistically significant difference.
Abbreviations: Fev1, forced expiratory volume in one second; FvC, forced vital 
capacity; SD, standard deviation.
Table 1 Demographic characteristics of the study sample
Age/years Male  
n (%)
Female  
n (%)
Total  
n (%)
40–49 116 (32.5) 81 (19.6) 197 (25.5)
50–59 59 (16.5) 93 (22.4)  152 (20.0)
60–69 75 (21.0) 122 (29.5) 197 (25.5)
70+ 106 (30.0)  118 (28.5) 224 (29.0)
Notes: Chi-square value = 85,33; df = 3; P = 0.01. There is a statistically significant 
difference between male and female patients.
Table 2 Smoking status of the study participants
Smokers Male  
n (%)
Female  
n (%)
Total  
n (%)
Current 201 (56.5) 77 (18.6)  278 (36.1)
Former 57 (16.0) 121 (29.2) 178 (23.1)
Never 98 (27.5) 216 (52.2) 314 (40.8)
Notes: Chi-square value = 118,97; df = 2; P = 0.01. There is a statistically significant 
difference between male and female patients.
Table 4 Spirometry in the study participants
Spirometry Male  
n (%)
Female  
n (%)
Total  
n (%)
Normal 283 (79.4) 362 (87.4) 645 (83.8)
Airflow limitation 56 (15.7) 23 (5.5) 79 (10.2)
Restriction 17 (14.9) 29 ( 7.1) 46 ( 6.0)
Notes: Chi-square value = 22,35; df = 2; P = 0.01. There is a statistically significant 
difference between male and female patients.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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seen in men and women .70 years of age, which is similar 
to data obtained by other investigators.11,12 This fact must be 
considered with caution, because we and other investigators 
have used fixed ratio FEV1/FVC , 0.7 as the cutoff point 
for airflow obstruction.
In the present study, one-third of patients (31.6%) with 
COPD were aged 40–60 years, indicating the importance 
of the disease in the working population.33 Tzanakis et al 
detected nearly 40% of individuals with COPD aged 
40–60 years.34
Although the proportion of subjects younger than 
50 years with COPD is obviously lower than that of older 
individuals, we detected 7.6% such individuals. These rates 
are of interest because they represent a cohort of patients 
with a presumably long life expectancy, and a considerable 
contribution to the burden of the disease.35
An important finding of our study is that there was a huge 
gap between physician diagnosis of COPD and the presence of 
airflow obstruction defined by spirometry. Ninety-two   percent 
of our subjects did not report a prior physician diagnosis of 
COPD. Our participants were recruited so that they were 
self-selected and came to our hospital on a voluntary basis 
and were included in this study. Therefore, this rate (92%) 
most likely does not accurately represent the actual rate of 
undetected COPD in the target population, and did not provide 
population-based prevalence estimates. This discrepancy 
between physician diagnosis and obstruction defined by 
spirometry has also been reported by other investigators.32
Fourteen percent of our patients without a prior diagnosis 
of COPD had severe stages of the disease. Mannino et al 
reported that, among their participants, 63.3% of COPD cases 
was detected for the first time, and 44% of the patients who 
were detected had severe disease according to the GOLD 
classification.10 One of the reasons for the late detection of 
the disease is that the patients did not recognize the symptoms 
of the illness early enough.36 In order to improve early 
detection of COPD, spirometry as a routine investigation 
has been implemented in primary care settings in many 
countries.37–39
Conclusion
These results demonstrate that COPD, albeit in a mild form, 
was detected in one of every 10 tested patients. They also 
suggest that, with spirometry testing, patients with COPD 
could be detected in the earlier stages of the disease.
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